These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 15695591)

  • 41. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis.
    Kim Y; Sato K; Asagiri M; Morita I; Soma K; Takayanagi H
    J Biol Chem; 2005 Sep; 280(38):32905-13. PubMed ID: 16046394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway.
    Park KH; Park B; Yoon DS; Kwon SH; Shin DM; Lee JW; Lee HG; Shim JH; Park JH; Lee JM
    Cell Commun Signal; 2013 Oct; 11():74. PubMed ID: 24088289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation.
    Crotti TN; Flannery M; Walsh NC; Fleming JD; Goldring SR; McHugh KP
    Gene; 2006 May; 372():92-102. PubMed ID: 16513293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide.
    Koide N; Kaneda A; Yokochi T; Umezawa K
    Int Immunopharmacol; 2015 Mar; 25(1):162-8. PubMed ID: 25617668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
    Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
    Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
    Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
    Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
    PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanistic insight into osteoclast differentiation in osteoimmunology.
    Takayanagi H
    J Mol Med (Berl); 2005 Mar; 83(3):170-9. PubMed ID: 15776286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet-activating factor-induced chemokine gene expression requires NF-kappaB activation and Ca2+/calcineurin signaling pathways. Inhibition by receptor phosphorylation and beta-arrestin recruitment.
    Venkatesha RT; Ahamed J; Nuesch C; Zaidi AK; Ali H
    J Biol Chem; 2004 Oct; 279(43):44606-12. PubMed ID: 15308653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcium signaling in osteoclast differentiation and bone resorption.
    Kajiya H
    Adv Exp Med Biol; 2012; 740():917-32. PubMed ID: 22453976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
    Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
    Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
    Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
    J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism.
    Frick KK; Bushinsky DA
    J Bone Miner Res; 2003 Jul; 18(7):1317-25. PubMed ID: 12854843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
    Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
    J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
    Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H
    Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.